Compare Extra Space Storage, Inc. (EXR) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs GSK plc — how do they compare? Extra Space Storage, Inc. trades at $148.89 (market cap $30.56B), while GSK plc trades at $52.6 (market cap $101.34B). The key difference: GSK plc is far larger — about 3.3× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays the higher dividend (4.48%). Which is the better fit depends on your goals.
| EXR | GSK | |
|---|---|---|
Market Cap | $30.56B | $101.34B |
Sector | Real Estate | Health |
52-Week High | $152.75 | $61.18 |
52-Week Low | $126.67 | $36.20 |
Enterprise Value | $44.36B | $121.95B |
Dividend Yield | 4.48% | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXR trades at $148.89, up 2.33% over 24 hours, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.14 exceeding expectations. Revenue reached $3.38B in 2025, with a net income margin of 27.66%, though ROE remains modest at 6.92%. Recent news highlights steady expansion and a $550 million senior notes issuance, while analyst consensus is a $155.88 price target with a mix of Buy and Hold ratings.
Outlook is cautiously optimistic given consistent earnings performance and resilient demand, but risks include high debt levels, competitive pressures, and expense growth outpacing revenue. The stock's valuation metrics like P/E of 32.5 suggest it is priced for growth, yet investor sentiment is divided, with technical indicators showing neutral momentum near key support at $144.
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
